Are mutations in K-RAS, BRAF and PIK3CA genes critical for response to adjuvant trastuzumab treatment in patients with HER-2 positive breast cancer?

Anne Marie Bak Jylling, Anders Aamann Rasmussen, Erik Hugger Jakobsen, René dePont Christensen, Flemming Brandt Sørensen

Research output: Contribution to journalJournal articleResearchpeer-review

Original languageDanish
Article number3
JournalJournal of Cancer Therapeutics & Research
Issue number3
Publication statusPublished - 2014

Cite this